Ombitasvir相关论文
Efficacy and Safety of Ombitasvir plus Paritaprevir,Ritonavir and Ribavirin in Non-cirrhotic Treatme
Hepatitis C virus genotype 4(HCV-GT4)is a risk factor for cirrhosis,hepatocellular carcinoma and liver failure.A combina......
Viekira Pak是由帕利瑞韦(paritaprevir)、奥毕他韦(ombitasvir)、达萨布韦(dasabuvir)和利托那韦组成的复方制剂。由于本品能同时......
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction
We observed a sustained viral response(SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 1......
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction
We observed a sustained viral response(SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 1......
BACKGROUND The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), the HCV NS4/4A protease inhibitor ABT-4......
Technivie由美国AbbVie制药公司研发,2014年FDA授予其突破性药物资格,并通过优先审查程序进行了审批,于2015年7月24日上市。该药由......
